ICAP
AVDL

Independence Capital Asset Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Independence Capital Asset Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-54,500
Closed -$780K – 73
2014
Q3 		$780K Buy
54,500
+24,750
+83% +$356K 0.11% 64
2014
Q2 		$446K Buy
+29,750
New +$359K 0.06% 72

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Independence Capital Asset Partners's AVDL Position: Q4 2014 in Review

Independence Capital Asset Partners sold out of Avadel Pharmaceuticals (AVDL) in Q4 2014, closing a stake of 54,500 shares — an estimated $780K sold.

Independence Capital Asset Partners first reported a position in AVDL in Q2 2014 and held it in 2 quarters. The position peaked at $780K in Q3 2014. 94 funds tracked by Wall St. Rank hold AVDL as of Q4 2014.

  • Independence Capital Asset Partners reported no remaining Avadel Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Independence Capital Asset Partners sold 54,500 Avadel Pharmaceuticals shares in Q4 2014, an estimated $780K.
  • Independence Capital Asset Partners first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Independence Capital Asset Partners's Avadel Pharmaceuticals position peaked at $780K in Q3 2014.
  • 94 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2014.

Based on Independence Capital Asset Partners's 13F filing for Q4 2014, filed 13 Feb 2015.